Europe's First Public Quantum Company Just Listed in the U.S. — and the SPAC Is the Quiet Part

The SPAC question

Here’s where the story gets complicated. SPACs — Special Purpose Acquisition Companies — were the financial vehicle of choice during the 2021 market frenzy. Hundreds of companies went public through SPAC mergers, often at inflated valuations with projections that turned out to be fiction. The median SPAC that merged in 2021 has lost roughly 70% of its value. The mechanism became synonymous with hype-driven speculation. So when a quantum computing company announces a SPAC merger in 2026, the natural reaction is skepticism. Is this IQM finding the fastest path to public capital, or is it a company that couldn’t survive the scrutiny of a traditional IPO choosing the easier route? The honest answer is: it could be either, and we won’t know for a while. The bull case is straightforward. IQM has real revenue, real customers, and real hardware shipping to real facilities. The $1.8 billion valuation, while substantial, isn’t absurd relative to the company’s bookings trajectory and the size of the addressable market. Quantum computing is one of the few technology sectors where government spending is accelerating regardless of broader budget pressures [1]. The bear case is equally straightforward. Quantum computing has been “five years away” from commercial relevance for about twenty years. IQM’s $35 million in revenue is real but tiny relative to a $1.8 billion valuation — that’s a 51x revenue multiple. The SPAC structure historically attracts companies that prioritize speed to market over valuation discipline. And the quantum sector’s track record in public markets is poor: IonQ and Rigetti have both seen significant post-IPO declines. The Infleqtion comparison is instructive. That company — formerly ColdQuanta — went public on the NYSE recently, part of what appears to be a clustering of quantum IPOs [3]. When multiple companies in the same nascent sector rush to public markets simultaneously, it usually means one of two things: the technology is genuinely reaching a commercialization inflection point, or the window for raising capital on quantum hype is closing and everyone wants to get through it before it shuts.

The European angle

For Europe’s technology ecosystem, IQM’s story is bittersweet. On one hand, it’s a genuine success. A Finnish university spinout became the continent’s most valuable quantum company in under a decade. The €320 million Series B it raised last year was the largest quantum funding round in European history [1]. It has delivered more on-premises quantum systems than any competitor globally. That’s a legitimate accomplishment in a field dominated by American and Chinese companies. On the other hand, IQM is listing in New York, not Helsinki or Frankfurt. The company’s leadership clearly concluded that U.S. capital markets offer better liquidity, higher valuations, and more investor sophistication in deep tech than anything available in Europe. That’s probably true — and it’s the same calculation that has driven European tech companies to U.S. markets for decades. The potential Helsinki dual listing feels like a consolation prize. The real capital formation, the real investor base, and the real market-making will happen on Nasdaq or NYSE. Finland gets a flag on the building; America gets the company. This dynamic — European innovation, American capitalization — is one of the continent’s most persistent technology policy failures. The EU has spent billions on quantum research programs. IQM is arguably the biggest commercial success story to emerge from that investment. And the primary financial beneficiaries will be American institutional investors.

What to watch

IQM’s SPAC merger will likely close in Q2 or Q3 2026. Between now and then, several things will determine whether this is a landmark moment for quantum commercialization or another cautionary SPAC tale. First, the redemption rate. SPAC shareholders can redeem their shares before the merger closes. High redemption rates (above 80%) would suggest institutional investors aren’t confident in the valuation. Low redemption rates would signal genuine buy-in. Second, the PIPE. Most SPAC mergers include a Private Investment in Public Equity component where institutional investors commit capital alongside the merger. The size and quality of IQM’s PIPE investors will say a lot about how sophisticated money views the company. Third, the post-merger trading. SPACs typically experience significant volatility in their first weeks. A stock that holds or appreciates would validate the thesis. A stock that drops 40% in the first month — as many 2021 SPACs did — would confirm the skeptics. IQM has real technology, real customers, and real revenue in a sector with real government tailwinds. It also has a SPAC structure, a rich valuation, and the ghost of a hundred failed quantum promises haunting its investor deck. The next six months will tell us which of those facts matters more.